CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 122 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,047 | +64.9% | 35,217 | 0.0% | 0.01% | +83.3% |
| Q2 2023 | $635 | -18.3% | 35,217 | -27.2% | 0.01% | -25.0% |
| Q1 2023 | $777 | -5.6% | 48,355 | +7.5% | 0.01% | -11.1% |
| Q4 2022 | $823 | -99.9% | 44,989 | 0.0% | 0.01% | -10.0% |
| Q3 2022 | $884,000 | +45.9% | 44,989 | +63.0% | 0.01% | +66.7% |
| Q1 2022 | $606,000 | -22.7% | 27,597 | 0.0% | 0.01% | -14.3% |
| Q4 2021 | $784,000 | +34.9% | 27,597 | 0.0% | 0.01% | +40.0% |
| Q3 2021 | $581,000 | – | 27,597 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 3,375,169 | $84,379,000 | 7.91% |
| RA Capital Management | 1,875,209 | $46,880,000 | 2.52% |
| Perceptive Advisors | 2,587,953 | $64,698,000 | 1.48% |
| New Leaf Venture Partners, L.L.C. | 167,700 | $4,193,000 | 1.12% |
| Orbimed Advisors | 2,039,282 | $50,982,000 | 0.79% |
| Eventide Asset Management | 803,839 | $20,096,000 | 0.61% |
| Novo Holdings A/S | 135,009 | $3,375,000 | 0.47% |
| Opaleye Management Inc. | 36,000 | $900,000 | 0.27% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 490,000 | $12,250,000 | 0.03% |
| Baker Brothers Advisors | 132,985 | $3,325,000 | 0.02% |